C. Nicholas Hodge, Amphora's CSO and founder, said: “We are delighted that Genentech sees the potential value of one of our early stage programs. I personally see this as validation of our ability to produce high quality drug candidates.”
Under the terms of the agreement, Genentech acquired all of the intellectual property for the program, including the preclinical lead and several backup series.
Amphora said that it has multiple leads in oncology, inflammation, pain as well as metabolic and CNS disease. The US pharmaceutical company discovers and develops novel, targeted therapies for human diseases.